{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"Parathyroid hormone: Any increase in PTH was considered response","groups":[{"description":"Cohort A: Parathyroid hormone (participants received bortezomib 1.3 mg/m2 per days 1, 4, 8 and 11 for three 21-day cycles)","id":"OG000","title":"Cohort A"},{"description":"Cohort B: Parathyroid hormone (participants received bortezomib 1.0 mg/m2 per days 1, 4, 8 and 11 for three 21-day cycles)","id":"OG001","title":"Cohort B"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"6 months","title":"Number of Participants With a Positive Response to Bortezomib Measured by the Bone Marker Parathyroid Hormone","type":"PRIMARY","unitOfMeasure":"participants"}